GlassScriptPhysician profile
Waleed Obaid
NPI 1003187295
$1,093.81
in general payments reported to CMS, 2019-2025
18 companies · $16.71 in 2025
The $16.71 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $39.33 · 2021: $282 · 2022: $137 · 2023: $280 · 2024: $88.86 · 2025: $16.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $385.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $177.82 | 2021-2023 | Nayzilam, Briviact |
| Janssen Pharmaceuticals, INC | $162.59 | 2019-2023 | Xarelto |
| Melinta Therapeutics, LLC | $89.71 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $80.99 | 2019-2024 | |
| Pfizer INC. | $74.19 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $72.66 | 2019-2023 | Recarbrio, Zerbaxa, Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.76 | 2021-2023 | Stiolto Respimat, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $62.98 | 2019-2024 | Eliquis |
| Penumbra, INC. | $57.28 | 2022-2023 | Indigo System |
| Boston Scientific Corporation | $50.43 | 2020-2025 | Watchman Flx |
| La Jolla Pharmaceutical Company | $45.69 | 2023-2024 | Xerava |
| Paratek Pharmaceuticals, INC. | $39.35 | 2020-2022 | |
| Gilead Sciences, INC. | $29.86 | 2021 | |
| Philips North America LLC | $22.29 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $17.13 | 2023 | Arcalyst |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $15.00 | 2024 | Givlaari |
| Alexion Pharmaceuticals, INC. | $14.16 | 2022 | |
| Abbvie INC. | $12.92 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waleed Obaid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.